For years, Novo Nordisk and Eli Lilly have dominated the conversation surrounding obesity medicines as the duopoly competes to lead the largest pharmaceutical category in history.

While dozens of companies are chasing their frontrunner status, none have a commercial launch within the next few quarters, which makes the Lilly vs. Novo second-quarter showdown all the more valuable as to how the market will continue to play out. The drugmakers both report earnings on Aug. 5. Read more.